Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

Abbvie Inc (NYSE:ABBV) shares fell after hours on Wednesday after CVS Health Corp announced it will remove Humira, a leading rheumatoid arthritis medication, from some preferred drug lists for reimbursement starting April 1, endorsing biosimilar alternatives. Sandoz's Hyrimoz and an unbranded version of Humira, along with Biocon's near-copy drugs, will be preferred on CVS formularies.

Abbvie shares down as CVS moves to replace top selling arthritis drug with cheaper alternatives

CVS Health said on Wednesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosimilar versions of the medicine instead.

CVS will remove AbbVie's Humira from some drug reimbursement lists in April

AbbVie pays a high yield of 4%, and it has been increasing its dividend for years. However, the company's latest rate hike was more modest than it has been in years past.

1 Concerning Trend for AbbVie Investors to Keep an Eye On

Chevron

Procter & Gamble

Target

T. Rowe Price Group

Exxon Mobil

The current market is characterized by price volatility and return uncertainty. However, seven companies span across various sectors—consumer staples, financial, healthcare, energy, industrials and more—each wielding a unique prowess in generating passive income.

7 Dividend Aristocrats With Boatloads of Passive Income Potential

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

As we break into the new year, investors are on the hunt for the best biotech stocks to buy. Indeed, 2024 could witness groundbreaking advancements in technology and science.

3 Biotech Stocks Set for Breakthroughs in 2024

Axsome Therapeutics

AbbVie's recent major patent cliff won't kill its returns throughout the next decade. Axsome Therapeutics is gaining in prominence thanks to an exciting late-stage pipeline.

2 Biotech Stocks You Can Buy and Hold for the Next Decade

NORTH CHICAGO, Ill. , Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P.

AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Bank of America

Lowe's

AbbVie is a Dividend King that's poised to return to solid growth. Bank of America has a strong record of dividend increases.

3 Top Dividend Growth Stocks to Buy in 2024

Philip Morris

You know what I hate about the typical article about hottest dividend stocks to watch? You're excited about adding passive income to your portfolio, only to read about company after company that pays a dividend yield of 1%.

The 3 Hottest Dividend Stocks to Watch in 2024

Archer-Daniels-Midland Company

Black Hills

Cincinnati Financial

Federal Realty Investment Trust

Fortis

Genuine Parts

Hormel Foods

Johnson & Johnson

Kenvue

Lancaster Colony

Leggett & Platt

Altria

National Fuel Gas

Northwest Natural Gas

United Bankshares

Universal Corp

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 54 Dividend Kings screened as of December 29 represented 9 of 11 Morningstar Sectors. Broker targeted-top-ten net-gains ranged 18.52%-38.49% topped-by Northwest Natural, and Altria Group. By yield, Altria tops-all. Top-ten Kingly January yields reported for ABBV, FTS, FRT, BKH, UVV, NWN, MMM, CDUAF, LEG, & MO averaged 5.45%.

January's 54 Dividend Kings: Buy 8, Watch 5

Brookfield Renewable Partners

Realty Income Corp

Dividend growth stocks tend to outperform, especially in flat to slightly higher markets. AbbVie, Brookfield Renewable, Realty Income, and T.

4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024

Colgate-Palmolive

Emerson Electric

JPMorgan Chase & Co

Kimberly-Clark

Walmart

Source: ferrantraite / E+ via Getty Images While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

7 Dividend Stocks Perfect For Retirement

ImmunoGen

AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

Novo Nordisk

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively.

Pharmaceutical stocks to watch in 2024

GlaxoSmithKline

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product launches, and strategic investments make it an attractive investment option.

AbbVie Vs. GSK: Dual Dominance In Pharma

Abbott Labs

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Church & Dwight

C.H. Robinson Worldwide

Clorox

Cintas Corp

Dover

Ecolab

The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats by quality score and provide undervalued stocks for further research and investment.

29 Undervalued Dividend Aristocrats: December 2023

AbbVie is a top drugmaker that is putting its free cash flow to use lately with a couple of acquisitions. Abbott Labs has a broader, more diverse business that recently generated double-digit growth.

Better Growth Stock: AbbVie vs. Abbott Laboratories

News for AbbVie Stock (ABBV)